STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands |
12 Months Ended |
Dec. 31, 2015 |
Dec. 31, 2014 |
Dec. 31, 2013 |
| Cash flows from operating activities: |
|
|
|
| Net income (loss) |
$ (885)
|
$ (677)
|
$ 8
|
| Adjustments required to reconcile net loss to net cash (used in) provided by operating activities: |
|
|
|
| Depreciation of property and equipment |
46
|
10
|
|
| Stock based compensation |
120
|
10
|
$ 58
|
| Decrease (increase) in other current assets |
(98)
|
(11)
|
17
|
| Increase (decrease) in current liabilities |
42
|
56
|
(43)
|
| Decrease (increase) in fair value of investment in BioCancell and gain/loss on sale of BioCancell securities |
35
|
245
|
(574)
|
| Net cash used in operating activities |
$ (740)
|
(367)
|
(534)
|
| Cash flows from investing activities: |
|
|
|
| Proceeds from sale of BioCancell securities |
|
67
|
$ 420
|
| Purchase of property and equipment |
$ (25)
|
(98)
|
|
| Net cash provided by (used for) investing activities |
(25)
|
$ (31)
|
$ 420
|
| Cash flows from finance activities: |
|
|
|
| Issuance of share capital |
603
|
|
|
| Net cash provided by finance activities |
603
|
|
|
| Decrease in cash and cash equivalents |
(162)
|
$ (398)
|
$ (114)
|
| Cash and cash equivalents at the beginning of the year |
8,722
|
9,120
|
9,234
|
| Cash and cash equivalents at the end of the year |
$ 8,560
|
$ 8,722
|
$ 9,120
|